Gilead Sciences Surges to 77th in Trading Volume with $977 Million Day After Supreme Court Ruling

On June 27, 2025, Gilead Sciences (GILD) saw a significant increase in trading volume, reaching $977 million, marking a 44.26% rise from the previous day. This surge placed Gilead at the 77th position in terms of trading volume for the day. The stock price of Gilead Sciences also rose by 2.82%, marking the second consecutive day of gains, with a total increase of 4.46% over the past two days.

The recent surge in Gilead's stock price can be attributed to a favorable ruling by the U.S. Supreme Court. The court upheld a federal mandate that requires health insurers to cover preventive care services, which is a crucial provision under the Affordable Care Act (ACA). This ruling is particularly beneficial for Gilead, as it ensures continued coverage for the company's HIV prevention drugs, removing a significant overhang that could have impacted the launch of new products like Yeztugo.

Analysts have responded positively to the court's decision. Morgan Stanley reiterated an Overweight rating and a $135 price target for Gilead, citing the favorable outcome of the Supreme Court ruling. The firm views this ruling as an incremental positive for Gilead, as it removes uncertainty and supports the company's future product launches.